Open Access
Review Article

September-October 2026, Vol. 02 (5), 60-75

International Journal of Pharmaceutical

Research and Medicinal Plants

(An International Peer Reviewed Journal)

Polymeric Nanoparticles for Drug Delivery

Kaviya Priya K*,
Ms. Subashini R, Ms. Kamali M.L. , Sri Priya E and Naresh Kannan S

Department of Biotechnology, KIT-Kalaignarkarunanidhi Institute of Technology, Coimbatore, Tamil Nadu, India

ARTICLE INFO:
ABSTRACT

Received:
09
th
Oct.
2026
;
Received
in
revised form: 16
th
Oct. 2026
;
Accepted:
27
th
Oct.
2026
;
Available
online:
30
th
Oct. 2026.

Keywords:
Polymeric nanoparticles,
Drug delivery, Stimuli-responsive,
Theranostics, 3D Printing, AI
Optimization, Green synthesis, Precision
medicine.

DOI:
https://doi.org/10.61280/774vgk83

*Corresponding Author:
Kaviya Priya K

Email:
kit.26.22bbt025@gmail.com

Polymeric
nanoparticles
(PNPs)
have
emerged
as
a
revolutionary
platform
in
drug
delivery,
offering
precise
control
over
therapeutic
release,
enhanced
targeting,
and
improved
pharmacokinetics.
This
review
comprehensively
examines
recent
advancements
in
PNP
design, focusing on smart stimuli-responsive systems that enable on-
demand drug release in
response to
pH, redox potential, or external
triggers
like
light
and
ultrasound
.Green
synthesis
approaches
using
biodegradable, eco-friendly polymers and solvent-free techniques are
addressing
sustainability
challenges
in
nanomedicine
.We
highlight
breakthroughs
in
theranostic
nanoparticles,
which
combine
therapy
and
diagnostics
through
integrated
imaging
agents,
facilitating
real-
time treatment monitoring. Innovations in 3D printing and AI-driven
optimization
are
transforming
PNP
fabrication,
allowing
for
personalized medicine through predictive modeling of drug-polymer
interactions and release kinetics. .Despite these advancements, critical
hurdles
remain
in
scalability,
long-term
biocompatibility,
and
regulatory
approval,
limiting
widespread
clinical
adoption.
Future
research
must
focus
on
enhancing
tumor
penetration,
optimizing
stealth coatings to evade immune clearance, and developing biohybrid
systems
such
as
cell-mimicking
nanoparticles.
The
integration
of
machine learning and autonomous feedback mechanisms promises to
user in a new era of precision drug delivery, while multi-drug-loaded
PNPs
could
revolutionize
combination
therapies
for
cancer
and
infectious
diseases.
As
the
field
progresses
toward
clinically
viable
solutions,
polymeric
nanoparticles
stand
at
the
forefront
of
next-
generation nanomedicine, poised to overcome existing limitations and
unlock transformative therapeutic potential.

1. INTRODUCTION

Nanoparticles
are ultra-small
particles ranging
from
1 to
100 nm
in
size. Due to
their tiny size
and high
surface area, they possess unique physical, chemical, and biological properties that differ significantly from
their
bulk
counterparts.
These
properties
make
nanoparticles
powerful
tools
in
various
scientific
and
industrial
fields,
especially
in
biomedicine
and
drug
delivery
.
One
of
the
main
advantages
of
nanoparticles
is their ability to interact at the cellular and molecular levels. They can penetrate biological

Copyright:
©
Author
2026
by
the
Author.
International
Journal
of
Pharmaceutical
Research
and
Medicinal
Plants
Published
by
Informative Journals
(Jadoun Science Publishing Group India). This article is an open access article distributed under the terms and conditions
of the CC BY-NC-ND 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 60

membranes, protect drugs from premature degradation, and be engineered to release drugs in a controlled or
targeted manner. Nanoparticles can improve drug solubility, stability, and bioavailability, which is especially
useful
for
drugs
that
are
poorly
absorbed
or
quickly
cleared
from
the
body
(De
Jong
&
Borm,
2008).
Additionally,
nanoparticles
can
reduce
side
effects
by
delivering
medication
directly
to
the
diseased
site,
minimizing
damage
to
healthy
tissues.
Due
to
these
benefits,
nanoparticles
have
found
applications
in
numerous areas such as cancer therapy, vaccine delivery, imaging, diagnostics, antimicrobial treatments, and
gene
therapy.
Their
role
in
personalized
medicine
is
also
growing,
as
they
can
be
designed
to
match
a
patient’s
specific
biological
needs.
Among
the
different
types
of
nanoparticles,
polymeric
nanoparticles
have gained significant attention in recent years (Sánchez et al., 2020).

These
are
nanoparticles
made
from
natural
or
synthetic
polymers
such
as
PLGA
(poly(lactic-co-glycolic
acid)),
chitosan,
PEG
(polyethylene
glycol),
and
polylactic
acid.
These
polymers
are
biodegradable,
biocompatible, and can be easily modified to suit various drug delivery needs. The
advantages of polymeric
nanoparticles
include their ability to encapsulate both hydrophilic (water-loving) and hydrophobic (water-
repelling) drugs, provide sustained or stimuli-responsive release, and avoid recognition and clearance by the
immune system. Their surfaces can be modified with ligands to achieve targeted delivery to specific tissues
or cells, such as cancer cells or infected tissues .In the
medical
field,
polymeric nanoparticles are widely
studied for delivering drugs in a safer, more effective, and more targeted manner. They are being explored for
the
treatment
of
cancer,
viral
and
bacterial
infections,
inflammatory
diseases,
neurological
disorders,
and
more (Couvreur, 2013). Despite their many benefits, challenges such as large-scale production, regulatory
hurdles, and long-term safety need to be addressed for broader clinical use.
As a result of these advantages,
polymeric
nanoparticles
are
attracting
significant
attention
for
intelligent
drug-delivery
designs
and
will
become increasingly vital as more innovative therapeutic cargo and treatments develop .Effective polymeric
nanoparticles
must
be
designed
to
migrate
a
myriad
of
biological
roadblocks
throughout
both
the
extracellular and intracellular environments.

These roadblocks are often specific to a particular drug, delivery route, disease, or endogenous target. For
example, the
challenges associated with
delivering low molecular weight
drugs, which include solubility,
toxicity,
and
controlled
release,
are
significantly
different
to
the
delivery
of
larger
therapeutics
such
as
proteins or nucleic acids, which generally require enhanced stability and targeted release at specific regions
within a cell. Thus, understanding how nanoparticles interact with each biological barrier, and which barriers
are
necessary
to
mitigate
for
a
given
disease/treatment,
is
crucial
to
designing
highly
efficient
polymeric
nanoparticles
for drug delivery. There has been
an immense research
effort over the last twenty
years to
develop polymeric nanoparticles that can more effectively respond to these biological challenges and thus
optimize therapeutic efficacy.

This
research
has
yielded
many
success
stories,
one
of
which
is
Abraxane,
an
albumin-bound
paclitaxel
formulation
that
was
approved
by
the
FDA
in
2005.
This
nanoparticle
is
based
on
the
conjugation
of
paclitaxel,
an
anti-cancer
drug,
with
albumin,
and
yields
superior
pharmacokinetics,
improved
tumor
inhibition
and
reduced
side
effects
compared
to
free
paclitaxel
(Begines
et
al.,
2020a)
.
More
recently,
injectable formulations have been approved to prolong the release of drugs for treatment of HIV (Apretude)
and Osteoporosis (Zilretta). Furthermore, Genexol-PM, a paclitaxel-loaded polymeric micelle, was approved
in
Korea
in
2007
for
the
treatment
of
breast,
lung
and
pancreatic
cancer.
As
well
as
these
commercial
products,
polymeric
nanoparticles
represent
many
drug-delivery
designs
currently
in
early-
and
late-stage
clinical trials.
Polymeric nanoparticles (PNPs) are nanoscale carriers, typically ranging from 10 to 1000 nm,
engineered
from
natural
or
synthetic
polymers
to
encapsulate
or
adsorb
therapeutic
agents.
These
nanoparticles are classified into nanospheres, where drugs are uniformly dispersed within a polymer matrix,
and
nanocapsules,
which
consist
of
a
polymeric
shell
surrounding
a
drug-loaded
core
.Polymeric
nanoparticles
(PNPs)
have
emerged
as
a
revolutionary
drug
delivery
platform,
offering
transformative
solutions
to
longstanding
challenges
in
medicine.
Their
significance
stems
from
their
unique
ability
to

Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 61

enhance drug efficacy
while minimizing adverse effects.
Conventional
drug delivery systems often suffer
from poor bioavailability, rapid clearance, and non-specific distribution, leading to suboptimal therapeutic
outcomes
and
unwanted
side
effects.
PNPs
address
these
limitations
by
encapsulating
drugs
within
biocompatible
polymer
matrices,
protecting
them
from
degradation
and
enabling
controlled
release
over
extended
periods(Beach
et
al.,
2024).
This
capability
is
particularly
valuable
for
drugs
with
narrow
therapeutic windows or those prone to enzymatic breakdown .A key advantage of PNPs is their ability to
facilitate targeted drug delivery, improving precision in treating diseases such as cancer. Passive targeting
leverages
the
enhanced
permeability
and
retention
(EPR)
effect,
where
nanoparticles
accumulate
preferentially in tumor tissues due to their leaky vasculature. Active targeting further enhances specificity by
conjugating
ligands
(e.g.,
antibodies,
peptides)
to
the
nanoparticle
surface,
enabling
selective
binding
to
overexpressed receptors on diseased cells. This targeted approach reduces systemic toxicity and enhances
therapeutic efficiency. Additionally, PNPs can overcome biological barriers, such as the blood-brain barrier
(BBB),
enabling
drug
delivery
to
previously
inaccessible
sites
like
the
central
nervous
system.
Beyond
small-molecule
drugs,
PNPs
are
versatile
carriers
for
macromolecules,
including
proteins,
nucleic
acids
(siRNA, mRNA), and even hydrophobic-hydrophilic drug combinations. Their tunable polymer composition
allows for stimuli-responsive behavior, where drug release is triggered by microenvironmental cues like pH,
temperature,
or
enzymes—ideal
for
site-specific
therapy.
The
clinical
success
of
formulations
like
Abraxane®
(albumin-bound
paclitaxel)
and
Onpattro®
(lipid-polymer
siRNA
delivery)
underscores
their
real-world
impact(Vijaykumar
et
al.,
2014).
With
ongoing
advancements
in
polymer
science
and
nanotechnology,
PNPs
continue
to
pave
the
way
for
next-generation
therapeutics,
offering
safer,
more
effective, and personalized treatment options.
Polymeric nanoparticles (PNPs) offer significant advantages
over
traditional
drug
delivery
systems,
such
as
oral
tablets,
injections,
and
liposomal
formulations,
by
overcoming
critical
pharmacological
limitations.
One
of
their
most
notable
benefits
is
enhanced
drug
bioavailability. Many therapeutic compounds, particularly hydrophobic drugs and biologics, suffer from poor
solubility and rapid degradation in the gastrointestinal tract or bloodstream. PNPs encapsulate these drugs,
protecting them from enzymatic degradation and improving their dissolution properties, thereby increasing
systemic absorption and therapeutic efficacy(Kumari et al., 2010).

Another
major
advantage
is
the
ability
to
achieve
controlled
and
sustained
drug
release.
Conventional
formulations often lead to rapid drug clearance, requiring frequent dosing and resulting in fluctuating plasma
concentrations. In contrast, polymeric nanoparticles can be engineered to release drugs gradually over hours,
days, or even weeks, depending on the polymer’s degradation rate (e.g., PLGA for long-term release). This
reduces
dosing
frequency,
enhances
patient
compliance,
and
maintains
therapeutic
drug
levels
within
the
optimal range, minimizing toxicity(Wu et al., 2020). Perhaps the most transformative feature of PNPs is their
targeted
delivery
capability.
Unlike
conventional
drugs,
which
distribute
non-specifically
throughout
the
body, PNPs can passively accumulate in diseased tissues (e.g., tumors via the EPR effect) or actively target
specific cells through surface modifications with ligands like antibodies, peptides, or aptamers.

This
precision
minimizes
off-target
effects,
reduces
systemic
toxicity,
and
enhances
drug
potency
at
the
desired site. Additionally, PNPs enable delivery across biological barriers(e.g., blood-brain barrier, mucosal
membranes)
that
are
typically
impermeable
to
standard
drugs.
Their
versatility
extends
to
co-delivery
of
multiple therapeutics (e.g., chemotherapeutic drugs with siRNA) and stimuli-responsive release(e.g., pH- or
temperature-triggered drug activation in tumors). With successful clinical applications like Abraxane® and
Onpattro®, PNPs demonstrate superior performance over conventional systems, offering a smarter, safer, and
more effective approach to modern medicine(Jawahar & Meyyanathan et al., 2012).

Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 62

Fig:1-Overview
of
polymeric
nanoparticles
as
multifunctional
drug
delivery
systems
integrating
therapeutic
agents
for
targeted,
sustained,
and
controlled
release
across
various
biomedical
applications(Begines et al., 2020b).

Polymeric nanoparticles (PNPs) offer distinct advantages over other nanocarriers like liposomes, micelles,
and inorganic nanoparticles, making them a versatile choice for drug delivery. Compared to liposomes which
have excellent biocompatibility but suffer from stability issues and premature drug leakage—PNPs provide
superior
structural
integrity,
controlled
drug
release,
and
the
ability
to
encapsulate
both
hydrophilic
and
hydrophobic
drugs.
While
polymeric
micelles
are
effective
for
solublizing
hydrophobic
drugs,
their
instability at low concentrations limits their utility, whereas PNPs maintain their structure and offer higher
drug-loading capacity(Castro et al., 2022). In contrast to inorganic nanoparticles (e.g., gold or iron oxide),
which provide unique diagnostic and therapeutic functionalities but raise long-term toxicity concerns due to
non-degradability, PNPs are biodegradable and more easily functionalized for targeted delivery. Although
each
nanocarrier
has
its
niche—liposomes
for
mRNA
vaccines,
micelles
for
paclitaxel
delivery,
and
inorganic nanoparticles for imaging and hyperthermia—PNPs stand out for their balanced combination of
tunable drug release, high stability, and adaptability to diverse therapeutic needs, making them a preferred
platform for advanced drug delivery applications
(Crucho & Barros et al., 2017)

WORKFLOW

Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 63
POLYMERIC
NANOPARTICLE
ENCAPSULATED
WITH DRUG
TARGETED SITE OF
DISEASES
AI IS INVOLVED TO
IMPROVE THE
PRECISIONOF DRUG
CONTROLLED DRUG
RELEASE RESULT IN
HIGH
BIOAVAILABILITY

2. POLYMERIC NANOPARTICLES

2.1 TYPES OF POLYMERS

Polymeric nanoparticles can be fabricated using either natural or synthetic polymers, with natural polymers
like chitosan, alginate, gelatin, and hyaluronic acid offering distinct advantages for drug delivery applications
due to their inherent biocompatibility, biodegradability, and low immunogenicity(Crucho & Barros, 2017b).
Chitosan, a cationic polysaccharide derived from chitin, exhibits mucoadhesive properties and can enhance
drug absorption across epithelial barriers, making it particularly useful for oral and nasal delivery systems.
Alginate,
an
anionic
polysaccharide
from
brown
algae,
forms
gentle
gel-like
nanoparticles
under
mild
conditions, ideal for encapsulating sensitive biomolecules like proteins and peptides. Gelatin, obtained from
collagen
hydrolysis,
provides
excellent
biodegradability
and
has
been
widely
used
in
controlled
release
formulations,
while
its
modifiable
functional
groups
allow
for
easy
surface
conjugation(Bhatia,
2016).
Hyaluronic
acid,
a
glycosaminoglycan
naturally
present
in
extracellular
matrices,
offers
active
targeting
capabilities through its affinity for CD44 receptors overexpressed in cancer cells and inflamed tissues. These
natural
polymers
not
only
facilitate
drug
encapsulation
and
protection
but
also
often
exhibit
intrinsic
therapeutic properties, such as chitosan's antimicrobial activity or hyaluronic acid's wound-healing potential,
making them particularly valuable for developing multifunctional nanomedicines with enhanced therapeutic
efficacy and reduced side effects. Synthetic polymers have become the cornerstone of advanced polymeric
nanoparticle systems due to their precisely tunable properties and reproducible manufacturing. Among the
most
widely
used,
PLGA
(poly(lactic-co-glycolic
acid))
stands
out
for
its
excellent
biocompatibility
and
controllable
degradation
rate,
which
can
be
finely
adjusted
by
varying
the
lactide-to-glycolide
ratio
to
achieve drug release profiles ranging from days to months.

Its FDA-approved status for various medical applications makes it particularly valuable for controlled drug
delivery. PLA (polylactic acid), a related polyester, offers slower degradation kinetics and higher mechanical
strength, though with less flexibility in degradation rate modulation compared to PLGA. PEG (polyethylene
glycol) is frequently incorporated as a surface coating to confer "stealth" properties, significantly prolonging
circulation time by reducing opsonization and reticuloendothelial system clearance(Banik et al., 2016). PCL
(polycaprolactone), with its exceptionally slow degradation rate (up to years), finds particular utility in long-
term implantable drug delivery systems. Beyond these conventional synthetic polymers, stimuli-responsive
polymers
represent
a
revolutionary
advancement
in
smart
drug
delivery.
pH-
sensitive
polymers,
such
as
poly(β-amino
esters),
undergo
structural
changes
in
the
acidic
tumor
microenvironment
or
cellular
endosomes,
enabling
precise
site-specific
drug
release.
Temperature-sensitive
polymers
like
poly(N-
isopropylacrylamide) exhibit reversible phase transitions at physiological temperature ranges, allowing for
thermally triggered drug delivery. Redox-sensitive polymers containing disulfide bonds rapidly degrade in
the
high
glutathione
concentration
of
cancer
cells,
facilitating
intracellular
drug
release.
These
intelligent
materials
respond to
specific pathological
signals
or externally applied triggers, creating opportunities for
highly
sophisticated,
spatiotemporally
controlled
therapeutic
systems
that
maximize
drug
efficacy
while
minimizing
off-target
effects.
The
combination
of
synthetic
polymers'
reliability
with
stimuli-responsive
systems precision represents the cutting edge of targeted nanomedicine development(Vauthier & Bouchemal,
2009).

2.2 FABRICATION METHOD

The production of polymeric nanoparticles (PNPs) involves various techniques, each with distinct advantages
and limitations in terms of scalability, reproducibility, drug-loading efficiency, and particle size control(Rane
et al., 2018a). Below, we explore the key methods and their critical aspects.

Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 64

Fig:3-Various method involved in fabrication of PNPs

1. Emulsion-Solvent Evaporation

This
widely
used
method
involves
dissolving
the
polymer
and
drug
in
an
organic
solvent
(e.g.,
dichloromethane),
emulsifying
it
in
an
aqueous
phase
containing
a
stabilizer
(e.g.,
PVA),
and
then
evaporating the solvent to form solid nanoparticles. The advantages include high encapsulation efficiency,
suitable for hydrophobic drugs, scalable for industrial production. Limitation includes required surfactants,
residual
solvent
removal
needed,
and
particle
size
depends
heavily
on
homogenization
energy(G.
Nava-
Arzaluz et al., 2012).

2. Nanoprecipitation (Solvent Displacement Method)

A simple and rapid technique where a polymer solution is injected into a non-solvent (e.g., water), causing
spontaneous nanoparticle formation due to interfacial deposition. The Advantages are no high-energy mixing
required,
produces
small
and
uniform
particles
(~50–300
nm),
suitable
for
lab-scale
synthesis.
Some
Limitations are poor encapsulation of hydrophilic drugs, limited control over particle size distribution
(Shinde
& More, n.d.)
.

3. Polymerization Techniques

There
are
two
techniques
for
polymerization
which
includes,
Emulsion
polymerization
and
Interfacial
polymerization.
In
emulsion
Polymerization,
monomers
are
polymerized
in
an
aqueous
phase
with
surfactants,
forming
nanoparticles
in
situ
which
is
useful
for
synthetic
polymers
like
poly(alkyl
cyanoacrylates).Where
as
in
interfacial
Polymerization
the
two
reactive
monomers
meet
at
an
oil-water
interface, forming nanocapsules which is ideal for encapsulating fragile biomolecules. The advantages and
disadvantages are good control over particle size and polymer properties
,
potential toxicity from unreacted
monomers, complex purification steps respectively(C. Liu et al., 2020).

4. Supercritical Fluid Technology (SCF)

Uses
supercritical
CO₂
as
an
environmentally
friendly
alternative
to
organic
solvents.
Techniques
include supercritical antisolvent (SAS) precipitation and rapid expansion of supercritical solutions (RESS).
The advantages are no solvent residues, narrow size distribution, suitable for thermolabile drugs. Limitations
are High equipment cost, limited polymer compatibility(Sheth et al., 2012).

Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 65
Fabrication
method
Emulsion
-
Solvent
Evaporation
Nanoprecipitation
Microfluidics
-Based
Synthesis
Polymerization
Techniques
Supercritical
Fluid
Technology

5. Microfluidics-Based Synthesis

A cutting-edge approach where fluids are precisely mixed in microchannels to form nanoparticles with highly
controlled properties(Li et al., 2021).The advantages are excellent reproducibility, tunable size (10–500 nm),
ideal
for
complex
formulations
(e.g.,
lipid-polymer
hybrids).Where
as
limitations
are
Low
throughput,
challenges in large-scale manufacturing(Khizar et al., 2022).

Table:1-Comparison of different type of fabrication methods

Fabrication
Method

Scalability

Reproducibility

Particle Size
Control

Best For

Efficiency

Emulsion-Solvent
Evaporation

High

Moderate-High

Moderate
(100–500
nm)

Hydrophobic drugs,
PLGA NPs

60-75%

Nanoprecipitation

Moderate

High

Good (50–
300 nm)

Small-scale,
lipophilic drugs

80-90%

Polymerization

Moderate-
High

Moderate

Good (50–
400 nm)

In-situ synthesis of
nanospheres

65-80%

Supercritical
Fluids

Low-
Moderate

High

Excellent
(20–200 nm)

Solvent-free,
uniform NPs

50-70%

Microfluidics

Low

Very High

Excellent
(10–500 nm)

Precision-
engineered NPs

70-85%

3. PHARMACOKINETICS STUDIES

Polymeric nanoparticles employ two primary drug incorporation strategies: encapsulation within the polymer
matrix or surface adsorption. Encapsulation, typically used for hydrophobic drugs, provides superior drug
protection and controlled release, while adsorption allows for easier loading of hydrophilic compounds but
may lead to faster drug leakage. Several critical factors influence drug loading efficiency, including polymer-
drug
compatibility
(hydrophobic
drugs
pair
best
with
hydrophobic
polymers
like
PLGA),
the
chosen
fabrication method (emulsion techniques generally offer higher encapsulation yields than nanoprecipitation),
and specific drug-polymer interactions(Zur Mühlen et al., 1998). Drug release kinetics are governed by three
main
mechanisms
ie,
diffusion
through
the
polymer
matrix,
polymer
degradation
rate,
and
in
stimuli-
responsive systems, environmental triggers like pH or temperature changes. These release profiles can be
tailored for either sustained delivery (using slow-degrading polymers for chronic conditions) or burst release
(ideal
for
vaccines
or
acute
treatments).
The
design
strategy
depends
on
the
therapeutic
requirements
-
sustained release maintains therapeutic levels over extended periods, while burst release ensures rapid drug
availability. Advanced systems now combine these approaches, using stimuli-responsive polymers to create
"smart" nanoparticles that release drugs only at specific target sites, maximizing therapeutic efficacy while
minimizing
side
effects(Owens
&
Peppas,
2006).
These
technological
advances
continue
to
expand
the
applications of polymeric nanoparticles in precision medicine.

4. ENCAPSULATION VS ADSORPTION OF DRUGS IN POLYMERIC NANOPARTICLES

Polymeric nanoparticles utilize two distinct approaches for drug incorporation: encapsulation and adsorption,
each
with
unique
advantages
and
limitations.
Encapsulation
involves
the
physical
entrapment
of
drug
molecules within the polymer
matrix during nanoparticle formation, creating a protected reservoir system.
This method is particularly advantageous for hydrophobic drugs, as it provides high loading capacity, shields
the drug from degradation, and enables controlled release kinetics. The encapsulation efficiency depends on

Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 66

factors like polymer-drug compatibility,
with
hydrophobic polymers (e.g., PLGA, PCL) showing superior
encapsulation
for
lipophilic
compounds(Cheow
&
Hadinoto,
2011).
In
contrast,
adsorption
relies
on
the
surface
attachment
of
drug
molecules
to
pre-formed
nanoparticles
through
electrostatic
interactions,
hydrogen
bonding,
or
hydrophobic
forces.
While
adsorption
facilitates
easier
loading
of
hydrophilic
or
charged
molecules
and
allows
for
faster
drug
release,
it
may
result
in
premature
drug
leakage
and
lower
loading capacity compared to encapsulation(Cohen et al., 2000). The choice between these strategies depends
on the drug's physicochemical properties, desired release profile, and therapeutic application - encapsulation
being preferred for sustained delivery systems, while adsorption may be suitable for rapid-onset therapies or
when
maintaining
drug
stability
is
less
critical.
Recent
advances
have
enabled
hybrid
approaches
that
combine both encapsulation and adsorption to achieve optimized drug loading and tailored release profiles
for complex therapeutic needs (Pinto Reis et al., 2006).

4.1 SURFACE MODIFICATION AND FUNCTIONALIZATION STRATEGIES FOR POLYMERIC
NANOPARTICLES

The surface engineering of polymeric nanoparticles has emerged as a transformative approach to overcome
biological barriers and achieve targeted drug delivery. PEGylation remains the gold standard for conferring
stealth
properties,
where
polyethylene
glycol
chains
(typically
2-20
kDa)
form
a
hydrophilic
corona
that
reduces opsonization and extends circulation half-life through steric stabilization(Mauri et al., 2017). Recent
advances in PEG chemistry have introduced branched architectures and cleavable linkages (pH-, enzyme-, or
redox-sensitive) that address limitations of traditional linear PEG, including the accelerated blood clearance
phenomenon observed in some patients. Beyond PEGylation, alternative stealth polymers such as poly(2-
oxazoline) and zwitterionic materials are gaining attention for their reduced immunogenicity and superior
protein
resistance.
For
active
targeting,
a
diverse
array
of
ligands
including
monoclonal
antibodies
(e.g.,
trastuzumab
for
HER2+
cancers),
engineered
antibody
fragments
(scFv,
nanobodies),
and
peptide
motifs
(RGD, TAT) enable receptor-specific delivery, while aptamers like AS1411 offer advantages of small size
and thermal stability. Small molecule targeting approaches utilizing folate, biotin, or carbohydrate moieties
provide additional options for tissue-specific accumulation. Surface charge engineering plays a critical role in
biodistribution,
where
cationic
nanoparticles
(potential
+15
to
+25
mV)
facilitate
mucosal
adhesion
and
blood-brain
barrier
penetration
through
adsorptive
transcytosis,
while
anionic
surfaces
exhibit
reduced
nonspecific
interactions
and
improved
tumor
penetration(Choi
et
al.,
2003).
Emerging
multi-functional
systems combine these approaches through innovative designs such as charge-switching nanoparticles that
transition from neutral/anionic during circulation to cationic at target sites, or "masked" ligands that only
expose
targeting
moieties
in
response
to
disease-specific
stimuli.
Advanced
characterization
techniques
including
X-ray
photoelectron
spectroscopy,
time-of-flight
secondary
ion
mass
spectrometry,
and
surface
plasmon resonance are essential for verifying surface modifications and quantifying ligand density. As the
field progresses, bioinspired approaches incorporating cell membrane coatings and biomimetic surfaces are
showing promise for enhanced immune evasion and tissue homing. However, challenges remain in scaling up
production
of
surface-engineered
nanoparticles
while
maintaining
batch-to-batch
consistency
and
meeting
regulatory
requirements
for
novel
excipients.
Future
directions
point
toward
increasingly
sophisticated
systems featuring dynamic, environmentally responsive surfaces capable of adapting their properties in real-
time
to
optimize
drug
delivery,
as
well
as
personalized
approaches
that
tailor
surface
modifications
to
individual
patient
characteristics.
These
surface
engineering
strategies
are
transforming
polymeric
nanoparticles
from
simple
drug
carriers
to
intelligent,
multifunctional
delivery
systems
with
precisely
controlled
interactions
in
biological
environments
.This
comprehensive
surface
modification
approach
enables fine-tuning of nanoparticle pharmacokinetics, biodistribution, and cellular uptake, addressing critical
challenges
in
drug
delivery
ranging
from
overcoming
biological
barriers
to
achieving
cell-specific
targeting(Ahmed
et
al.,
2021).
The
continued
development
of
novel
surface
engineering
techniques,
combined with improved analytical methods and manufacturing processes, promises to further enhance the

Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 67

therapeutic
potential
of
polymeric
nanoparticles
across
a
wide
range
of
medical
applications.
As
our
understanding of nanoparticle-biological interactions deepens, surface modification strategies are evolving
from
empirical
approaches to
rationally designed systems
based on computational
modeling
and artificial
intelligence,
paving
the
way
for
next-generation
nanomedicines
with
unprecedented
precision
and
efficacy(Patil
et
al.,
2009).
These
advances
position
surface-engineered
polymeric
nanoparticles
at
the
forefront of targeted drug delivery, with growing clinical impact in oncology, neurology, and regenerative
medicine.

Fig:4 Polymeric Nanoparticles for Targeted Drug Delivery: Design, Biological Journey, and
Therapeutic Action

5.
BIOLOGICAL CHALLENGES AND THE PROTEIN CORONA PHENOMENON

A pivotal, yet often underappreciated, barrier to the clinical translation of polymeric nanoparticles is their
dynamic interaction with the biological milieu, culminating in the formation of a “protein corona” (Kopac,
2021).Upon
intravenous
administration,
PNPs
are
immediately
immersed
in
a
complex
biological
fluid,
leading to the rapid and spontaneous adsorption of a layer of plasma proteins and other biomolecules onto
their surface. This protein corona does not merely represent a passive coating; it fundamentally redefines the
nanoparticle's
biological
identity,
effectively
masking
the
meticulously
engineered
surface
properties,
including
targeting
ligands
such
as
antibodies,
peptides,
or
aptamers.
This
obfuscation
can
severely
compromise active targeting strategies, rendering them ineffective as the nanoparticle's interactions with cell
receptors are dictated by the corona's composition rather than the underlying ligand. Furthermore, the corona
dictates the subsequent biological fate of the PNP, influencing its cellular uptake mechanisms, biodistribution
profile, and propensity for clearance by the mononuclear phagocyte system (MPS)(Heidarzadeh et al., 2023).
The
composition
of
the
corona
is
highly
variable
and
depends
on
the
nanoparticle's
original
surface
chemistry,
size,
and
shape,
as
well
as
individual
patient
factors,
introducing
a
significant
element
of
unpredictability
and
batch-to-batch
variability
that
complicates
clinical
outcomes.
In
response
to
this
challenge, current research is focused on developing sophisticated surface engineering strategies to mitigate
or
control
corona
formation.
These
include
the
use
of
ultra-hydrophilic
and
neutrally
charged
"stealth"
coatings
beyond
traditional
PEG,
such
as
poly(2-oxazoline)s
and
zwitterionic
polymers,
which
exhibit
superior protein resistance. An alternative, innovative approach involves the pre-formation of a "synthetic" or
"custom" corona with specific, functional proteins to deliberately
steer the nanoparticle towards a desired
biological pathway, thereby transforming a potential obstacle into a tool for precision delivery. Addressing
the protein corona is not merely an optimization step but a fundamental prerequisite for designing PNPs that
perform predictably and effectively in the complex human physiological environment(Neagu et al., 2017).

Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 68

6. PHARMACODYNAMICS STUDIES

The release profile of encapsulated drugs from polymeric nanoparticles is governed by complex, interrelated
mechanisms that can be tailored for specific therapeutic needs. Three primary mechanisms dominate drug
release
kinetics
are
(1)diffusion-controlled
release,
where
drug
molecules
gradually
migrate
through
the
polymer
matrix
-
this
mechanism
predominates
in
hydrophobic
polymers
with
low
degradation
rates
are
(2)erosion/degradation-controlled release, where hydrolytic or enzymatic breakdown of polymer chains (e.g.,
ester hydrolysis in PLGA) governs release rates, particularly important for sustained delivery systems; and
(3) stimuli-responsive release, triggered by microenvironmental cues like pH shifts in tumors (pH 6.5-7.0),
elevated
glutathione
levels
in
cancer
cells
(redox-sensitive),
or
external
triggers
like
temperature
or
light(Kamaly
et
al.,
2016).
The
release
kinetics
follow
characteristic
patterns
-
initial
burst
release
from
surface-associated drug, followed by diffusion-mediated release, and finally degradation-controlled release as
the polymer matrix breaks down. Mathematical
models (Higuchi,
Korsmeyer-Peppas) help
quantify these
processes, where release exponents indicate whether diffusion (n=0.5) or erosion (n=1.0) dominates. Smart
engineering
allows
precise
temporal
control
-
from
immediate
release
(hours)
for
acute
treatments
to
prolonged
release
(weeks-months)
for
chronic
conditions.
Current
advances
focus
on
multi-stage
release
systems
combining
these mechanisms, such
as
nanoparticles providing initial
rapid
release for immediate
effect followed by sustained release for prolonged therapy, all while responding to biological triggers for site-
specific
delivery.
These
sophisticated
release
profiles
are
revolutionizing
treatment
paradigms
across
oncology, infectious diseases, and regenerative medicine(Bohrey et al., 2016).

7. FACTORS AFFECTING DRUG LOADING EFFICIENCY IN POLYMERIC NANOPARTICLES

The
drug
loading
efficiency
of
polymeric
nanoparticles
is
influenced
by
multiple
interrelated
factors
that
must be carefully optimized for each therapeutic applications are,

1. Polymer-Drug Compatibility

The physicochemical compatibility between the drug and polymer is fundamental. Hydrophobic drugs (e.g.,
paclitaxel, curcumin) exhibit superior loading in hydrophobic polymers like PLGA or PCL due to favourable
partitioning. For hydrophilic drugs (e.g., proteins, nucleic acids), hydrophilic polymers such as chitosan or
alginate
are
preferred,
often
requiring
additional
strategies
like
ion
pairing
or
chemical
conjugation.
Amphiphilic drugs present unique challenges and may require polymer blends or surface-modified carriers.
Recent advances include the development of zwitterionic polymers that can accommodate both hydrophobic
and hydrophilic moieties(J. Liu et al., 2004).

2. Fabrication Method Selection

The
nanoparticle
production
technique
significantly
impacts
loading
capacity
are
emulsion-solvent
evaporation
provides
excellent
encapsulation
(60-90%)
for
lipophilic
drugs
but
may
denature
biologics
,nanoprecipitation
achieves
moderate
loading
(30-70%)
for
small
molecules
but
poor
retention
of
macromolecules
,spray
drying
enables
high
throughput
but
may
cause
thermal
degradation
,microfluidic
methods
offer
precise
control
but
currently
have
limited
scalability
,emerging
techniques
like
electrohydrodynamic processes show promise for high-efficiency loading of sensitive biomolecules(Rane et
al., 2018b).

3. Drug-Polymer Interactions

The nature of intermolecular forces critically affects both loading and release are hydrophobic interactions
dominate
in
PLGA/drug
systems
,ionic
interactions
are
exploited
in
chitosan-based
carriers
,hydrogen
bonding influences protein loading in gelatin nanoparticles,π-π stacking can enhance loading of aromatic
compounds ,excessive drug-polymer affinity can create "retention effects" that impede complete drug release,
requiring careful balance
(Bookwala & Wildfong, 2023)
.

Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 69

4. Particle Characteristics

The Size are chosen from Sub-100nm particles have higher surface area but reduced core volume ,porosity
includes controlled porosity can increase and capacity while maintaining structure ,the Surface charge are
zeta
potential
affects
both
loading
and
stability
and
morphology
of
particles
are
core-shell
vs
matrix
structures
offer
different
loading
advantages
.Understanding
these
multifactorial
relationships
enables
rational
design
of
nanoparticles
with
precisely
controlled
drug
loading
characteristics
tailored
to
specific
therapeutic requirements. Ongoing research focuses on developing predictive models and high-throughput
screening methods to accelerate formulation optimization(Wang et al., 2007).

8. RECENT ADVANCES AND EMERGING TRENDS

The
field
of
polymeric
nanoparticles
has
witnessed
transformative
innovations,
particularly
in
the
development
of
smart,
stimuli-responsive
systems
that
enable
precise
spatiotemporal
drug
release.
These
advanced
nanoparticles
respond
to
biological
cues
such
as
pH
gradients
(e.g.,
tumor
microenvironment),
redox
conditions
(e.g.,
high
glutathione
in
cancer
cells),
or
external
triggers
(light,
ultrasound),
allowing
for on-demand drug delivery(W. S. Khan et al.,
2025). Theranostic nanoparticles, integrating therapy and
diagnostics, now incorporate contrast agents (quantum dots, iron oxide) for real-time imaging and treatment
monitoring.
Another
breakthrough
is
the
3D
printing
of
polymeric
nanoparticles,
which
enables
precise
control
over
size,
shape,
and
drug-loading
parameters,
facilitating
personalized
medicine.
(Vora
et
al.,
2023)AI-driven
design
is
revolutionizing
formulation
optimization,
using
machine
learning
to
predict
polymer-drug
compatibility,
release
kinetics,
and
in
vivo
behavior,
significantly
reducing
trial-and-error
experimentation. Additionally, green synthesis approaches are gaining traction, with researchers developing
biodegradable,
eco-friendly
polymers
(e.g.,
plant-derived
polysaccharides)
and
solvent-free
fabrication
methods (supercritical CO₂) to enhance sustainability(Jain et al., 2014).

8.1. Biohybrid and Biomimetic Nanoparticles: Leveraging Biological Complexity

A paradigm shift in PNP design is emerging with the development of biohybrid and biomimetic systems,
which seek to circumvent biological barriers by co-opting natural biological structures and pathways. Rather
than relying solely on synthetic chemistry to evade immune detection, researchers are now fabricating PNPs
cloaked in natural cell membranes. This approach involves the extraction and fusion of lipid bilayers from
specific
cells
such
as
red
blood
cells
(RBCs),
leukocytes,
or
cancer
cells
onto
the
surface
of
synthetic
polymeric cores(Harun-Ur-Rashid
et al.,
2023). RBC membrane-coated PNPs,
for instance, display "self"
markers like CD47 that inhibit phagocytosis by macrophages, conferring dramatically prolonged circulation
half-lives
that
can
surpass
even
the
most
advanced
stealth
polymers.
Conversely,
leukocyte
membrane
coatings endow PNPs with the innate ability to target inflamed tissues and penetrate biological barriers like
the
blood-brain
barrier
by
mimicking
the
adhesion
and
transmigration
processes
of
immune
cells.
In
oncology, homotypic targeting is achieved by coating PNPs with membranes derived from the patient's own
cancer cells, exploiting their inherent affinity for self-progenitor cells within a tumor mass. This biomimetic
strategy represents a significant leap beyond traditional ligand-receptor targeting, as it presents a complex,
biologically authentic surface that can interact with the host environment in a more sophisticated and multi-
faceted
manner,
thereby
enhancing
targeting
precision,
improving
biocompatibility,
and
reducing
immunogenic responses(Ighodaro et al., 2024).

8.2. The Role of Artificial Intelligence and In Silico Modeling

The complexity of PNP design, governed by a multitude of interdependent variables, is increasingly being
untangled through the application of artificial intelligence (AI) and machine learning (ML). Moving beyond
simple
optimization,
AI-driven
platforms
are
now
capable
of
predicting
fundamental
properties
such
as
polymer-drug compatibility, which dictates encapsulation efficiency and release kinetics, by analyzing vast
chemical
datasets(Sinisi,
2021).
Machine
learning
models
can
process
experimental
parameters
from
the

Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 70

fabrication
process
including
polymer
molecular
weight,
solvent
choice,
surfactant
concentration,
and
homogenization speed—to predict and optimize resulting nanoparticle characteristics like size, zeta potential,
and
polydispersity
index
with
remarkable
accuracy,
drastically
reducing
the
traditional
"trial-and-error"
experimentation
cycle.
Furthermore,
the
emerging
concept
of
a
"digital
twin"—a
comprehensive
computational
model
of
a
PNP
that
simulates
its
behavior
in
a
virtual
physiological
environment
holds
immense promise. These in silico models can integrate data on PNP properties with known physiological
parameters
to
forecast
in
vivo
pharmacokinetics,
biodistribution,
and
even
therapeutic
efficacy
before
a
single nanoparticle is synthesized(Yash et al., 2025). This paradigm not only accelerates the development
timeline but also enables a more rational and resource-efficient design process, paving the way for highly
personalized nanomedicine where PNP formulations could be tailored and virtually tested against a patient-
specific digital avatar.

8.3. CLINICAL TRANSLATION AND COMMERCIAL LANDSCAPE

The
journey
of
polymeric
nanoparticles
from
laboratory
innovation
to
clinical
application
represents
the
ultimate validation of their therapeutic potential. While the path
is
fraught
with
challenges, several
PNPs
have successfully navigated the regulatory landscape, offering tangible clinical benefits. The most prominent
example remains Abraxane® (albumin-bound paclitaxel), which leverages endogenous albumin pathways to
enhance tumor targeting and eliminate the need for toxic solvents like Cremophor EL, thereby significantly
improving
the
safety
profile
of
paclitaxel
chemotherapy.
Beyond
this
flagship
product,
other
notable
successes include Genexol-PM, a paclitaxel-loaded polymeric micelle approved in South Korea for breast
and lung cancer, which demonstrates superior tumor accumulation through the EPR effect, and Onpattro®
(patisiran),
a
lipid
nanoparticle
formulation
for
siRNA
delivery
that,
while
not
a
pure
PNP,
shares
core
principles
with
polymer-based
systems
and
validates
the
broader
nanocarrier
approach
for
nucleic
acid
therapeutics. These successes, however, belie the significant
attrition rate of PNP
formulations in clinical
development(Vargason et al., 2018). A critical analysis reveals that many promising candidates fail in late-
stage trials due to a confluence of factors. A primary reason is the lack of a substantial therapeutic advantage
over
existing
standard-of-care
treatments,
where
improved
efficacy
fails
to
materialize
in
heterogeneous
human
patient
populations.
Furthermore,
unexpected
immunogenic
responses,
such
as
complement
activation-related pseudoallergy (CARPA) or the accelerated blood clearance (ABC) phenomenon associated
with repeated dosing of PEGylated nanoparticles, can halt development(M. N. Khan, 2020). Crucially, the
translation from robust efficacy in murine models to humans is often hampered by the oversimplification of
animal models, which fail to fully recapitulate the complexity and variability of human tumors, particularly
the heterogeneity of the EPR effect. This translational gap is compounded by the formidable challenge of
scaling up laboratory synthesis methods such as nanoprecipitation or microfluidics to industrial-scale Good
Manufacturing Practice (GMP) production. Maintaining stringent control over critical quality attributes like
particle size, polydispersity index, and drug loading efficiency at a large scale is non-trivial and economically
demanding, often leading to batch-to-batch variations that can impact clinical outcomes. Therefore, the future
clinical success of PNPs hinges not only on scientific innovation but also on a deliberate focus on developing
robust, scalable, and economically viable manufacturing processes alongside clinical trial designs that can
genuinely demonstrate a superior risk-benefit profile in well-defined patient populations(Hua et al., 2018).

9. CONCLUSION AND FUTURE PERSPECTIVES

In
conclusion,
polymeric
nanoparticles
have
unequivocally
established
themselves
as
a
cornerstone
of
modern drug delivery, evolving from simple inert carriers to sophisticated, multifunctional platforms capable
of
targeted,
stimuli-responsive,
and
theranostic
applications.
This
review
has
delineated
the
journey
from
their
fundamental
building
blocks
biocompatible
natural
and
synthetic
polymers
and
the
fabrication
techniques that define their physical
properties, to
the advanced
engineering of their surfaces and release
kinetics aimed at overcoming biological barriers(Patel et al., 2012). The clinical success of formulations like

Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 71

Abraxane® and Genexol-PM underscores the transformative potential of this technology, validating years of
intensive research and development. However, the path from laboratory innovation to widespread clinical
adoption remains fraught with significant challenges. The persistent issues of scalable manufacturing, batch-
to-batch
reproducibility,
and
a
comprehensive
understanding
of
long-term
biocompatibility
continue
to
impede
progress.
Furthermore,
the
biological
complexity
of
the
in
vivo
environment,
epitomized
by
the
protein corona phenomenon and the heterogeneity of human pathophysiology, reveals a critical gap between
pre-clinical promise and clinical efficacy that must be bridched.

Looking forward, the future of polymeric nanoparticles lies in embracing complexity and intelligence across
multiple fronts. First, the next generation of PNPs must be inherently "smarter." This involves developing
multi-stage, adaptive systems that can sequentially overcome barriers: for instance, particles that maintain a
stealthy, neutral charge during circulation, then become positively charged for enhanced tissue penetration,
and finally, release their payload only upon encountering a specific intracellular trigger like high glutathione
levels.
Second,
the
paradigm
of
biomimicry
must
be
fully
leveraged(Gagliardi
et
al.,
2021).
Biohybrid
nanoparticles,
cloaked
in
natural
cell
membranes,
offer
a
revolutionary
approach
to
achieving
superior
immune evasion and tissue-specific homing, effectively tricking the body's own defense mechanisms. Third,
the integration of artificial intelligence and machine learning will be indispensable. Moving beyond heuristic
formulation,
AI-driven
predictive
modeling
and
the
creation
of
"digital
twins"
for
nanoparticles
will
accelerate
the
rational
design
of
PNP
systems,
optimizing
their
properties
in
silico
before
synthesis
and
dramatically
reducing
development
timelines.
Finally,
a
concerted
focus
on
translational
science
is
paramount. Future research must prioritize robust, scalable, and economically viable Good Manufacturing
Practice (GMP)-compliant production methods from the outset(Yash et al., 2025). Simultaneously, clinical
trials need to be designed with a sharper focus on patient stratification, leveraging biomarkers to identify
individuals
most
likely
to
benefit
from
nanotherapeutic
interventions.
As
we
stand
at
the
confluence
of
nanotechnology, bioengineering, and data science, polymeric nanoparticles are poised to usher in a new era
of precision medicine, offering truly personalized, effective, and safe therapeutic solutions for some of the
most
daunting
diseases,
including
cancer,
neurodegenerative
disorders,
and
antibiotic-resistant
infections.
The
next
decade
will
undoubtedly
witness
these
innovations
transition
from
compelling
proof-of-concept
studies to clinically viable therapies that reshape the therapeutic landscape.

REFERENCES:

  1. 1.
    Banik, B. L., Fattahi, P., & Brown, J. L.(2016). Polymeric nanoparticles: The future of nanomedicine.
    Wiley
    Interdisciplinary
    Reviews:
    Nanomedicine
    and
    Nanobiotechnology,
    8(2),
    271–299.
    https://doi.org/10.1002/WNAN.1364
  2. 2.
    Beach, M. A., Nayanathara , U.,
    Gao, Y., Zhang, C., Xiong , Y., Wang, Y., &
    Such, G. K.(2024).
    Polymeric
    Nanoparticles
    for
    Drug
    Delivery.
    Chemical
    Reviews,
    124(9),
    5505–5616.
    https://doi.org/10.1021/ACS.CHEMREV.3C00705
  3. 3.
    Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez , G., Merinero, M., Argüelles-Arias, F., & Alcudia,
    A.(2020).
    Polymeric
    Nanoparticles
    for
    Drug
    Delivery:
    Recent
    Developments
    and
    Future
    Prospects.
    Nanomaterials, 10(7), 1403. https://doi.org/10.3390/NANO10071403
  4. 4.
    Bhatia, S.(2016). Nanoparticles Types, Classification, Characterization, Fabrication Methods and Drug
    Delivery Applications .Natural Polymer Drug Delivery Systems, 33–93. https://doi.org/10.1007/978-3-
    319-41129-3_2
  5. 5.
    Bohrey,
    S.,
    Chourasiya,
    V.,
    &
    Pandey,
    A.(2016).
    Polymeric
    nanoparticles
    containing
    diazepam:
    Preparation,
    optimization,
    characterization,
    in-vitro
    drug
    release
    and
    release
    kinetic
    study.
    Nano
    Convergence, 3(1), 1–7. https://doi.org/10.1186/S40580-016-0061-2
Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 72
  1. 6.
    Bookwala,
    M.,
    &
    Wildfong,
    P.
    L.
    D.(2023).
    The
    Implications
    of
    Drug-Polymer
    Interactions
    on
    the
    Physical
    Stability
    of
    Amorphous
    Solid
    Dispersions.
    Pharmaceutical
    Research,
    40(12),
    2963–2981.
    https://doi.org/10.1007/S11095-023-03547-4
  2. 7.
    Castro, K. C. de, Costa, J. M., & Campos, M. G. N.(2022). Drug-loaded polymeric nanoparticles: a
    review
    .International
    Journal
    of
    Polymeric
    Materials
    and
    Polymeric
    Biomaterials,
    71(1),
    1–13.
    https://doi.org/10.1080/00914037.2020.1798436
  3. 8.
    Cheow,
    W.
    S.,
    &
    Hadino,
    K.
    (2011).
    Factors
    affecting
    drug
    encapsulation
    and
    stability
    of
    lipid–
    polymer
    hybrid
    nanoparticles.
    Colloids
    and
    Surfaces
    B:
    Biointerfaces,
    85(2),
    214–220.
    https://doi.org/10.1016/J.COLSURFB.2011.02.033
  4. 9.
    Choi,
    S. W., Kim,
    W.
    S., &
    Kim,
    J. H.(2003). Surface modification of functional
    nanoparticles for
    controlled
    drug
    delivery.
    Journal
    of
    Dispersion
    Science
    and
    Technology,
    24(3–4),
    475–487.
    https://doi.org/10.1081/DIS-120021803
  5. 10.
    Cohen, H., Levy, R. J., Gao, J., Fishbein , I., Kousaev, V., Sosnowski, S., Slomkowski, S., & Golomb,
    G.(2000). Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene
    Therapy, 7(22), 1896–1905. https://doi.org/10.1038/SJ.GT.3301318
  6. 11.
    Couvreur, P. (2013). Nanoparticles in drug delivery: Past, present and future. Advanced Drug Delivery
    Reviews, 65(1), 21–23. https://doi.org/10.1016/J.ADDR.2012.04.010
  7. 12.
    12.Crucho,
    C.
    I.
    C.,
    &
    Barros,
    M.
    T.
    (2017).
    Polymeric
    nanoparticles:
    A
    study
    on
    the
    preparation
    variables
    and
    characterization
    methods.
    Materials
    Science
    and
    Engineering:
    C,
    80,
    771–784.
    https://doi.org/10.1016/J.MSEC.2017.06.004
  8. 13.
    De
    Jong,
    W.
    H.,
    &
    Borm
    ,
    P.
    J.
    A.
    (2008).
    Drug
    delivery
    and
    nanoparticles:
    Applications
    and
    hazards.International Journal of Nanomedicine,3(2),133–149. https://doi.org/10.2147/IJN.S596
  9. 14.
    G.
    Nava-Arzaluz,
    M.,
    Pinon-Segundo,
    E.,
    Ganem-Rondero,
    A.,
    &
    Lechuga-Ballesteros,
    D.(2012).
    Single
    Emulsion-Solvent
    Evaporation
    Technique
    and
    Modifications
    for
    the
    Preparation
    of
    Pharmaceutical Polymeric Nanoparticles. Recent Patents on Drug Delivery & Formulation, 6(3), 209–
    223. https://doi.org/10.2174/187221112802652633
  10. 15.
    Jain,
    K.,
    Mehra,
    N.
    K.,
    &
    Jain,
    N.
    K.(2014).
    Potentials
    and
    emerging
    trends
    in
    nanopharmacology.
    Current Opinion in Pharmacology, 15(1), 97–106. https://doi.org/10.1016/J.COPH.2014.01.006
  11. 16.
    Jawahar, N., & Meyyanathan, S. (2012). Polymeric nanoparticles for drug delivery and targeting: A
    comprehensive
    review.
    International
    Journal
    of
    Health
    &
    Allied
    Sciences,
    1(4),
    217.https://go.gale.com/ps/i.do?p=AONE&sw=w&issn=22784292&v=2.1&it=r&id=GALE%7CA3241
    13001
  12. 17.
    Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016). Degradable controlled-release polymers
    and
    polymeric
    nanoparticles:
    Mechanisms
    of
    controlling
    drug
    release.
    Chemical
    Reviews,
    116(4),
    2602–2663. https://doi.org/10.1021/ACS.CHEMREV.5B00346
  13. 18.
    Khan,
    W.
    S.,
    Asmatulu,
    E.,
    &
    Asmatulu,
    R.
    (2025).
    Nanotechnology
    emerging
    trends,
    markets
    and
    concerns. Nanotechnology Safety, 1–21. https://doi.org/10.1016/B978-0-443-15904-6.00017-4
  14. 19.
    Khizar,
    S.,
    Zine,
    N.,
    Errachid,
    A.,
    Jaffrezic-Renault,
    N.,
    &
    Elaissari,
    A.(2022).
    Microfluidic-based
    nanoparticle
    synthesis
    and
    their
    potential
    applications.
    ELECTROPHORESIS,
    43(7–8),
    819–838.
    https://doi.org/10.1002/ELPS.202100242
Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 73
  1. 20.
    Kumari, A., Yadav, S. K., & Yadav, S. C.(2010). Biodegradable polymeric nanoparticles based drug
    delivery
    systems.
    Colloids
    and
    Surfaces
    B:
    Biointerfaces,
    75(1),
    1–18.
    https://doi.org/10.1016/J.COLSURFB.2009.09.001
  2. 21.
    Li,
    W.,
    Chen,
    Q.,
    Baby,
    T.,
    Jin
    ,
    S.,
    Liu,
    Y.,
    Yang,
    G.,
    &
    Zhao,
    C.
    X.(2021).
    Insight
    into
    drug
    encapsulation in polymeric nanoparticles using microfluidic nanoprecipitation. Chemical Engineering
    Science, 235, 116468. https://doi.org/10.1016/J.CES.2021.116468
  3. 22.
    Liu, C., Hong, C. Y., & Pan, C. Y. (2020). Polymerization techniques in polymerization-induced self-
    assembly (PISA).Polymer Chemistry, 11(22), 3673–3689. https://doi.org/10.1039/D0PY00455C
  4. 23.
    Liu,
    J.,
    Xiao,
    Y.,
    &
    Allen,
    C.
    (2004).
    Polymer–drug
    compatibility:
    A
    guide
    to
    the
    development
    of
    delivery systems for the anticancer agent, ellipticine. Journal of Pharmaceutical Sciences, 93(1), 132–
    143. https://doi.org/10.1002/JPS.10533
  5. 24.
    Mauri, E., Papa, S., Masi, M., Veglianese, P., & Rossi, F. (2017). Novel functionalization strategies to
    improve
    drug
    delivery
    from
    polymers.
    Expert
    Opinion
    on
    Drug
    Delivery,
    14(11),
    1305–1313.
    https://doi.org/10.1080/17425247.2017.1285280
  6. 25.
    Patil, Y. B., Toti, U. S., Khdair, A., Ma, L., & Panyam, J.(2009). Single-step surface functionalization
    of
    polymeric
    nanoparticles
    for
    targeted
    drug
    delivery.
    Biomaterials,
    30(5),
    859–866.
    https://doi.org/10.1016/J.BIOMATERIALS.2008.09.056
  7. 26.
    Pinto Reis, C., Neufeld, R. J., Ribeiro, A. J., & Veiga, F. (2006). Nanoencapsulation I. Methods for
    preparation
    of
    drug-loaded
    polymeric
    nanoparticles.Nanomedicine:
    Nanotechnology,Biology
    and
    Medicine, 2(1), 8–21. https://doi.org/10.1016/J.NANO.2005.12.003
  8. 27.
    Rane, A. V., Kanny, K., Abitha, V. K., & Thomas, S. (2018). Methods for Synthesis of Nanoparticles
    and
    Fabrication
    of
    Nanocomposites.
    Synthesis
    of
    Inorganic
    Nanomaterials:
    Advances
    and
    Key
    Technologies, 121–139. https://doi.org/10.1016/B978-0-08-101975-7.00005-1
  9. 28.
    Sánchez,
    A.,
    Mejía,
    S.
    P.,
    &
    Orozco,
    J.(2020).
    Recent
    Advances
    in
    Polymeric
    Nanoparticle-
    Encapsulated
    Drugs
    against
    Intracellular
    Infections.
    Molecules,
    25(16),
    3760.
    https://doi.org/10.3390/MOLECULES25163760
  10. 29.
    Sheth, P., Sandhu, H., Singhal, D., Malick, W., Shah, N., & Serpil Kislalioglu, M.(2012). Nanoparticles
    in
    the
    Pharmaceutical
    Industry
    and
    the
    Use
    of
    Supercritical
    Fluid
    Technologies
    for
    Nanoparticle
    Production.Current Drug Delivery, 9(3), 269–284. https://doi.org/10.2174/156720112800389052
  11. 30.
    Shinde,
    A.
    J.,
    &
    More,
    H.
    N.
    (n.d.).
    Formulation,
    development
    and
    characterization
    of
    Simvastatin
    nanoparticles by solvent displacement method. Retrieved from www.scholarsresearchlibrary.com
  12. 31.
    Vauthier,
    C.,
    &
    Bouchemal,
    K.(2009).
    Methods
    for
    the
    Preparation
    and
    Manufacture
    of
    Polymeric
    Nanoparticles.Pharmaceutical Research, 26(5), 1025–1058. https://doi.org/10.1007/S11095-008-9800-3
  13. 32.
    Vijaykumar, O., Felix Joe, V., & Vishwanath, B. A.(2014). Formulation and evaluation of rivastigmine
    loaded polymeric nanoparticles. Journal of Chemical and Pharmaceutical Research, 6(10), 556–565.
  14. 33.
    Vora,
    L.
    K.,
    Gholap,
    A.
    D.,
    Jetha,
    K.,
    Thakur,
    R.
    R.
    S.,
    Solanki,
    H.
    K.,
    &
    Chavda,
    V.
    P.(2023).
    Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics, 15(7),
    1916. https://doi.org/10.3390/PHARMACEUTICS15071916
  15. 34.
    Wang,
    X.,
    Hall,
    J.
    E.,
    Warren,
    S.,
    Krom,
    R.,
    Magistrelli,
    J.
    M.,
    Rackaitis,
    M.,
    &
    Bohm,
    G.
    G.
    A.
    (2007). Synthesis, characterization, and application of novel polymeric nanoparticles. Macromolecules,
    40(3), 499–508. https://doi.org/10.1021/MA0613739
Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 74
  1. 35.
    Wu, S., Helal-Neto, E., Matos, A. P. dos S., Jafari, A., Kozempel, J., Silva, Y. J. de A., Serrano-Larrea,
    C., Alves Junior, S., Ricci-Junior, E., Alexis, F., & Santos-Oliveira, R.(2020). Radioactive polymeric
    nanoparticles
    for
    biomedical
    application.
    Drug
    Delivery,
    27(1),
    1544–1561.
    https://doi.org/10.1080/10717544.2020.1837296
  2. 36.
    Zur Mühlen, A., Schwarz, C., &
    Mehnert, W.(1998). Solid lipid
    nanoparticles (SLN)
    for
    controlled
    drug
    delivery
    –
    Drug
    release
    and
    release
    mechanism.
    European
    Journal
    of
    Pharmaceutics
    and
    Biopharmaceutics, 45(2), 149–155. https://doi.org/10.1016/S0939-6411(97)00150-1

How to cite this article:
Kaviya Priya K, Subashini R, Kamali M.L., Sri Priya E, Naresh Kannan S, Polymeric Nanoparticles for Drug
Delivery (2026).
International Journal of Pharmaceutical Research and Medicinal Plants
,
2
(5),60-75.
https://doi.org/10.61280/774vgk83

Published by:

Informative Journals

Jadoun Science Publishing Group India

Kaviya Priya K
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol. 2 (5), 60-75
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 75